<DOC>
	<DOCNO>NCT00690430</DOCNO>
	<brief_summary>The purpose randomize , multicenter , Phase III study compare efficacy paseriotide LAR octreotide LAR patient whose disease-related symptom inadequately control currently available somatostatin analogue .</brief_summary>
	<brief_title>Efficacy Safety Pasireotide Long Acting Release vs. Octreotide Long Acting Release Patients With Metastatic Carcinoid Disease</brief_title>
	<detailed_description />
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion criterion : Male female patient age 18 great Patients carcinoid tumor symptom ( diarrhea flush ) adequately control somatostatin analogue . Female patient child bear potential must negative pregnancy test baseline . Patients write informed consent participate study obtain . Exclusion criterion : Patients receive radiolabeled somatostatin analogue therapy within 3 month cytotoxic chemotherapy interferon therapy within 4 week prior randomization Diabetic patient antidiabetic medication whose fast blood glucose poorly control indicated HBA1C &gt; 8 % Patients symptomatic cholelithiasis Patient malabsorption syndrome , short bowel cholegenic diarrhea control specific therapeutic mean . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Carcinoid</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>gastroenteropancreatic</keyword>
	<keyword>somatostatin analogue</keyword>
	<keyword>Symptomatic Refractory Resistant Carcinoid Disease</keyword>
</DOC>